Mechanisms of pharmacokinetic and pharrnacodynamic drug interactions associated with ritonavir-enhanced tipranavir

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 888-909

  Vourvahis, Manoli ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretrovirals; CYP; Cytochrome P450; Drug safety; Drug drug interactions; HIV; Human immunodeficiency virus; Infectious disease; Nonantiretrovirals; Pharmacokinetics; Tipranavir ritonavir

Indexed keywords

BETA GLUCURONIDASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; RITONAVIR; TIPRANAVIR; UNINDEXED DRUG; CYTOCHROME P450; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE;

AREA UNDER THE CURVE; DRUG CONTRAINDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; REVIEW; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; PYRIDINES; PYRONES; RITONAVIR;

EID: 34249814621     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.888     Document Type: Review

References (211)

1. Sax PE. FDA approval: tipranavir [letter]. AIDS Clin Care 2005;3.
2. Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir. Antiviral drugs advisory committee (AVDAC) briefing document, NDA 21-814. Ridgefield, CT; 2005.
3. Boehringer Ingelheim Pharmaceuticals, Inc. Aptivus (tipranavir) package insert. Ridgefield, CT; 2005.
4. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003;34(suppl 1):S91-4.
5. Rusconi S, La Seta Catamancio S, Citterio P, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000;44:1328-32.
6. Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000;14:1943-8.
7. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998;41:3467-76.
8. McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:376-82.
9. Croom KE, Keam SJ. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 2005;65:1669-77.
10. Zhang D, Chando TJ, Everett DW. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-39.
11. Abbott Laboratories. Kaletra (lopinavir-ritonavir) package insert. North Chicago, IL; 2005.
12. van Heeswijk R, Sabo JP, MacGregor TR, et al. The effect of tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers [abstract]. Poster presentation at the 5th international workshop on clinical pharmacology in HIV therapy, Rome, Italy, April 1-3, 2004:abstract 4.8.
13. van Heeswijk R, Sabo J, MacGregor T, et al. The effect of tipranavir/ritonavir 500/200 mg bid (TPV/r) on the pharmacokinetics (PK) of clarithromycin (CLR) in healthy volunteers [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:abstract A-457.
14. van Heeswijk R, Sabo J, MacGregor T, et al. The pharmacokinetic (PK) interaction between single-dose rifabutin (RFB) and steady-state tipranavir/ritonavir 500/200 mg bid (TPV/r) in healthy volunteers [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:abstract A-456.
15. van Heeswijk R, Sabo JP, Cooper C, et al. The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP3A4 in healthy volunteers [abstract]. Poster presentation at the 5th international workshop on clinical pharmacology in HIV therapy, Rome, Italy, April 1-3, 2004:abstract 5.2.
16. Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (Pgp): implications for drug interactions [abstract]. Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, February 25-28, 2007:abstract 563.
17. Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005;49:4903-10.
18. Sabo JP, Elgadi M, Wruck J, et al. The pharmacokinetic interaction between atazanavir/ritonavir (ATV/r) and steady-state tipranavir/ritonavir (TPV/r) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy, Lisbon, Portugal, April 20-22, 2006:abstract 41.
19. Roszko PJ, Curry K, Brazina B, et al. Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r) [abstract]. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment, Paris, France, July 13-16, 2003:abstract 865.
20. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections, Denver, CO, February 5-9, 2006:abstract 583.
21. Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518 [abstract]. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2006:abstract A-374.
22. Abel S, Taylor-Worth R, Ridgway C, Weissgerber G, Kraft M. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK427.857) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy, Lisbon, Portugal, April 20-22, 2006:abstract 77.
23. Fontas E, van Leth F, Sabin CA, et al, for the D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74.
24. Boehringer Ingelheim Pharmaceuticals, Inc. Aptivus: drug interactions. Ridgefield, CT; 2005.
25. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998;87:190-4.
26. Grub S, Bryson H, Goggin T, Lüdín E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001;57:115-21.
27. Osanai T, Ohkubo T, Yasui N, Kondo T, Kaneko S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol 2004;58:476-81.
28. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
29. McCallister S, Sabo JP, Mayers DL, Galitz L. An open-label, steady-state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal, healthy volunteers (BI 1182.5) [abstract]. Poster presentation at the 9th conference on retroviruses and opportunistic infections, Seattle, WA, February 24-28, 2002:abstract 434-W.
30. Boffito M, Bonora S, Sales P, et al. Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. AIDS Res Hum Retroviruses 2003;19:941-2.
31. Crommentuyn KML, Mulder JW, Sparidans RW, Huitema ADR, Schellens JHM, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis [online exclusive article]. Clin Infect Dis 2004;38:e73-5. Available from http://www.journals.uchicago.edu/C1D/journal/issues/v38n8/32378/ 32378.html.
32. DeBeule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61(suppl 1):27-37.
33. Pfizer, Inc. Vfend (voriconazole) package insert. New York, NY; 2006.
34. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-7.
35. Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003;56(suppl 1):62-8.
36. Liu P, Foster G, Labadie R, Allison MJ, Sharma A. Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects [abstract]. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, Florida, March 2-6, 2005:abstract PI-123.
37. De Cock KM, Grant A, Porter JDH. Preventative therapy for tuberculosis in HIV-infected persons: international recommendations, research and practice. Lancet 995;345:833-6.
38. Bock N, Reichman LB. Tuberculosis and HIV/AIDS: epidemiological and clinical aspects (world perspective). Semin Respir Crit Care Med 2004;25:337-44.
39. U.S. Public Health Service (USPHS); Infectious Diseases Society of America (IDSA). 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001;2:493-554.
40. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, for the Centers for Disease Control and Prevention (CDC), National Institutes of Health, and Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004;53(RR-15):1-112. (Erratum in MMWR Morb Mortal Wkly Rep 2005;54:311.)
41. Justesen US, Andersen ÅB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis 2004;38:426-9.
42. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002;72:524-35.
43. Macgregor TR, Sabo JP, Norris SH, Johnson P. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004;5:371-82.
44. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
45. Shafran SD, Singer J, Zarowny DP, et al, for the Canadian HIV Trials Network Protocol 010 Study Group. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
46. Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6b-hydroxycortisol. Clin Pharmacol Ther 2002;72:33-43.
47. Abbott Laboratories. Biaxin (clarithromycin) package insert. North Chicago, IL; 2006.
48. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 2004;21:1284-93.
49. Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999;65:428-38.
50. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-16.
51. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.
52. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
53. Dube MP, Stein JH, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee and the HIV Medical Association of the Infectious Disease Society of America. 2003 Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the adult AIDS clinical trials group. Clin Infect Dis 2003;37:613-27.
54. Palacios R, Santos J, Gonzalez RM, et al. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:536-7.
55. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002;16:569-77.
56. Benesic A, Zilly M, Kluge F, et al. Lipid-lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004;32:229-33.
57. Doser N, Kübli S, Telenti A, et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002;16:1982-3.
58. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35.
59. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-5.
60. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-18.
61. Goebel FD, Sabo JP, MacGregor TR, Mayers DL, McCallister S. Pharmacokinetic drug interaction screen of three doses of tipranavir/ritonavir in HIV-infected patients on stable highly active antiretroviral therapy [abstract]. Presented at HIV DART frontiers in drug development for antiretroviral therapies, Naples, FL, December 15-19, 2002.
62. Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 1998;42:1592-6.
63. Agouron Pharmaceuticals, Inc. Viracept (nelfinavir mesylate) package insert. La Jolla, CA; 2006.
64. GlaxoSmithKline Pharmaceuticals. Ziagen (abacavir) prescribing information. Research Triangle Park, NC; 2006.
65. Boehringer Ingelheim Pharmaceuticals, Inc. Viramune (nevirapine) package insert. Ridgefield, CT; 2005.
66. Bristol-Meyers Squibb Company. Sustiva (efavirenz) package insert. Princeton, NJ; 2005.
67. Sabo JP, MacGregor T, Lamson MJ, Baldwin J, Borin M. Pharmacokinetics of tipranavir and nevirapine: a pharmacokinetic interaction study in healthy volunteers [abstract]. Presented at HIV DART frontiers in drug development for antiretroviral therapies, Isla Verde, Puerto Rico, December 17-21, 2000:abstract 103.
68. Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation NNRTI [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:abstract A-1827.
69. Piscitelli S, Baede P, Van't Klooster G, et al. TMC125 does not alter lopinavir/ritonavir (LPV/RTV) pharmacokinetics in healthy volunteers [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:abstract A-1824.
70. Boffito M, Winston A, Fletcher C, et al. Pharmacokinetics and antiretroviral response to TMC-114/r and TMC125 combination in patients with high level viral resistance [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections, Denver, CO, February 5-9, 2006:abstract 767c.
71. Dupuis ML, Cianfriglia M, Costi R, et al. HIV-1 integrase inhibitors are potent substrates for the MDR1 multidrug transporter [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections, Denver, CO, February 5-9, 2006:abstract 566.
72. Weber R, Ledergerber B, Zbinden R, et al. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV cohort study. Arch Intern Med 1999;159:1473-80.
73. Simon D, Brandt LJ. Diarrhea in patients with the acquired immunodeficiency syndrome. Gastroenterology 1993;105:1238-42.
74. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PF, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 2006;62:463-72.
75. Jackson LS, Stafford JE. The evaluation and application of a radioimmunoassay for the measurement of diphenoxylic acid, the major metabolite of diphenoxylate hydrochloride (Lomotil), in human plasma. J Pharmacol Methods 1987;18:189-97.
76. Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel report October 10, 2006. Bethesda, MD: Department of Health and Human Services, 2006.
77. Bliss DZ, Jung HJ, Savik K, et al. Supplementation with dietary fiber improves fecal incontinence. Nurs Res 2001;50:203-13.
78. Hawkins T. Nelfinavir-induced diarrhea is manageable with nonprescription medications [abstract]. Presented at the international AIDS conference, Geneva, Switzerland, June 28-July 3, 1998:abstract 12401.
79. Roe DA, Kalkwarf H, Stevens J. Effect of fiber supplements on the apparent absorption of pharmacological doses of riboflavin. J Am Diet Assoc 1988;88:211-13.
80. Razzeca K, Odenheimer S, Davis N, Landeck K. The treatment of nelfinavir-induced diarrhea [abstract]. Presented at the international AIDS conference, Geneva, Switzerland, June 28-July 3, 1998:abstract 12383.
81. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-6.
82. Trivier JM, Libersa C, Belloc C, Lhermitte M. Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 1993;52:PL91-6.
83. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 1997;43:245-52.
84. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994;55:256-69.
85. Komura H, Iwaki M. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates. Xenobiotica 2005;35:575-87.
86. Tham TCK, MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 1993;21:507-12.
87. Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos 1996;24:447-55.
88. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78(8A):12-16.
89. de Lannoy IAM, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551-7.
90. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999;66:391-400.
91. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994;27:1-5.
92. Abramowicz M, ed. Fexofenadine. Med Lett Drugs Ther 1996;38:95-6.
93. Koehler PJ, Isler H. The early use of ergotamine in migraine: Edward Woakes' report of 1868, its theoretical and practical background and its international reception. Cephalalgia 2002;22:686-91.
94. Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine, and ritonavir [online exclusive article]. Clin Infect Dis 2003;37:e72-3. Available from http://www.journals.uchicago.edu/CID/ journal/issues/v37n5/30843/30843.html.
95. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205.
96. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67:498-503.
97. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
98. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002;30:336-43.
99. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 1983;140:1183-6.
100. Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette's syndrome. J Am Acad Child Psychiatry 1984;23:161-73.
101. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-24.
102. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
103. Kang J, KWang I, Cai F, Rampe E. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol 2000;392:137-40.
104. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos 2003;31:243-9.
105. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005;78:520-8.
106. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69.
107. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998;23:55-9.
108. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-19.
109. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56(6 pt 1):601-7.
110. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
111. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
112. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
113. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36.
114. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JP, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-6.
115. Roche Laboratories, Inc. Klonopin (clonazepam) package insert. Nutley NJ; 2001.
116. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000;67:335-41.
117. Ghabrial H, Desmond PV, Watson KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986;30:93-7.
118. Patwardhan RV, Mitchell MC, Johnson RF, Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. Hepatology 1983;3:248-53.
119. Cato A III, Qian J, Hsu A, Levy B, Leonard J, Granneman R. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:1788-93.
120. Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retroviral 1998;19:260-5.
121. von Moltke LL, Greenblatt DJ, Granda,BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999;48:89-97.
122. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000;60:413-45.
123. Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 2002;32:849-62.
124. Renwick AB, Mistry H, Ball SE, et al. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998;28:337-48.
125. Wyeth Pharmaceuticals Inc. Sonata (zaleplon) package insert. Philadelphia, PA; 2004.
126. Sepracor, Inc. Lunesta (eszopiclone) package insert. Marlborough, MA; 2005.
127. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998;26:572-5.
128. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
129. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
130. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993;17:117-19.
131. Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991;163:414-15.
132. Wyatt CM, Murphy B. Kidney transplantation in HIV-infected patients. Semin Dial 2005;18:495-8.
133. Armstrong SC, Cozza KL, Pimentel EA. Immunosuppressants. Psychosomatics 2002;43:424-7.
134. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-44.
135. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003;37:1793-6.
136. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004;77:474-5.
137. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005;33:139-46.
138. Tsunoda SM, Aweeka FT. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. Biodrugs 2000;14:355-69.
139. Escousse A, Guedon F, Mounie J, Rifle G, Mousson C, D'Athis P. 6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. J Pharm Pharmacol 1998;50:1261-6.
140. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr 2005;40:573-80.
141. Arrington Sanders R, Hutton N, Siberry GK. Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 2006;25:1044-8.
142. GlaxoSmithKline, Inc. Flovent (fluticasone propionate) package insert. Research Triangle Park, NC; 2004.
143. AstraZeneca LP. Rhinocort Aqua (budesonide) package insert. Wilmington, DE; 2005.
144. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-94.
145. Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. J Clin Psychopharmacol 2003;23:652-6.
146. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989;45:366-72.
147. Hansten PD, Horn JR, eds. The top 100 drug interactions: a guide to patient management. Edmonds, WA: H&H Publications, 2004:157-69.
148. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride) package insert. Princeton, NJ; 2004.
149. Bayer Pharmaceuticals Corporation. Precose (acarbose) package insert. West Haven, CT; 2004.
150. Pfizer, Inc. Glyset (miglitol) package insert. New York, NY; 2006.
151. Pfizer, Inc. Viagra (sildenafil) package insert. New York, NY; 2005.
152. Bayer Healthcare. Levitra (vardenafil) package insert. West Haven, CT; 2005.
153. Eli Lilly and Company. Cialis (tadalafil) package insert. Indianapolis, IN; 2005.
154. Hendrix CW, Wakeford J, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 2004;24:1110-21.
155. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-82.
156. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methadone levels with nelfinavir mesylate [letter]. Am J Psychiatry 2000;157:481.
157. Sabo JP, Macha S, Oksala C, et al. Stereoselective pharmacokinetics (PK) of methadone after coadministration with steady-state tipranavir/ritonavir 500/200 mg bid (TPV/r) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy, Lisbon, Portugal, April 20-22, 2006;abstract 42.
158. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95.
159. Marinella MA. Meperidine-induced generalized seizures with normal renal function. South Med J 1997;90:556-8.
160. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995;23:490-6.
161. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999;91:681-5.
162. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
163. Hutchinson MR, Menelaou A, Foster DJR, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004;57:287-97.
164. Wilcox RA, Owen H. Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist. Anaesth Intensive Care 2000;28:611-19.
165. Jairaj M, Watson DG, Grant MH, Gray AI, Skellern GG. Comparative biotransformation of morphine, codeine and pholcodine in rat hepatocytes: identification of a novel metabolite of pholcodine. Xenobiotica 2002;32:1093-107.
166. Lotsch J, Schmidt R, Vetter G, et al. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 2002;83:241-8.
167. Huwyler J, Drewe J, Gutmann H, Thole M, Fricker G. Modulation of morphine-6-glucuronide penetration into the brain by P-glycoprotein. Int J Clin Pharmacol Ther 1998;36:69-70.
168. Huwyler J, Drewe J, Klusemann C, Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 1996;118:1879-85.
169. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001;158:725-30.
170. Eli Lilly and Company. Prozac (fluoxetine hydrochloride) prescribing information. Indianapolis, IN; 2005.
171. Pfizer, Inc. Zoloft (sertraline hydrochloride) prescribing information. New York, NY; 2005.
172. GlaxoSmithKline. Paxil (paroxetine hydrochloride) prescribing information. Philadelphia, PA; 2005.
173. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003;4:411-16. (Erratum in HIV Clin Trials 2004;5.)
174. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34:1838-44.
175. Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-19.
176. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999;290:1116-25.
177. Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982;65:998-1003.
178. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348:332-7.
179. Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78:143-53.
180. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-73.
181. Yeh R, Gaver V, Park J, et al. Lopinavir/ritonavir induces CYP2C9 and 2C19 activity, as measured by warfarin and omeprazole biomarkers in healthy human volunteers [abstract]. Presented at the 5th international workshop on clinical pharmacology of HIV therapy, Rome, Italy, April 1-3, 2004:abstract 4.1.
182. Ryan CT. New black box warning for ritonavir-boosted tipranavir [letter]. AIDS Clin Care 2006;4.
183. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS cohort study, 1985-1992. Neurology 1994;44:1892-900.
184. Rachlis AR. Neurologic manifestations of HIV infection: using imaging studies and antiviral therapy effectively. Postgrad Med 1998;103:147-61.
185. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol 1990;47:640-2.
186. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. Am J Med 1989;87:173-7.
187. Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro. II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005;33:1819-26.
188. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro. I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab Dispos 2002;30:1170-9.
189. Burman W, Orr L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS 2000;14:2793-4.
190. Hugen PW, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000;34:465-70.
191. Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos 2000;28:1361-8.
192. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans: a putative measure of CYP3A induction. J Pharm Sci 1995;84:292-4.
193. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004;36:1034-40.
194. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001;52:547-53.
195. DiCenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48:4328-31.
196. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
197. Ortho-McNeil Pharmaceuticals. Topamax (topiramate) package insert. Raritan, NJ; 2003.
198. Elan Pharmaceuticals. Zonegran (zonisamide) package insert. San Diego, CA; 2002.
199. Wallace Pharmaceuticals. Felbatol (felbamate) package insert. Goa, India; 2002.
200. Cephalon Pharmaceuticals. Gabitril (tiagabine) package insert. West Chester, PA; 2005.
201. UCB Pharma. Keppra (levetiracetam) package insert. Smyrna, GA; 2002.
202. GlaxoSmithKline. Lamictal (lamotrigine) package insert. Research Triangle Park, NC; 2003.
203. Pfizer. Neurontin (gabapentin) package insert. New York, NY; 2004.
204. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
205. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 2005;33:547-54.
206. Hennessy M, Kelleher D, Spiers JP, et al. St John's wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
207. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8. (Erratum in Lancet 2001;357:1210.)
208. Teixeira MH, Vilas-Boas LF, Gil VMS, Teixeira F. Complexes of ciprofloxacin with metal ions contained in antacid drugs. J Chemother 1995;7:126-32.
209. Antoniou T, Yoong D, Beique L, et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J Acquir Immune Defic Syndr 2005;39:126-8.
210. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 2006;26:511-14.
211. Winter D, Sauvard S, Stanescu C, Theodorescu M, Winter J, Nitelea I. The influence of metronidazole and disulfiram on the pharmacologic action of ethanol. Pharmacology 1969;2:27-31.